| 摘要 |
[Objectives] To explore the clinical efficacy of Qinjin Tablet in treating unstable angina with phlegm-stasis syndrome and preliminarily explore its intervention mechanism. [Methods] Sixty unstable angina patients with phlegm-stasis syndrome were randomly divided into a treatment group and a control group (30 each). The control group received standardized Western medicine treatment, while the treatment group also took Qinjin Tablet. After a 4-week treatment, comparisons were made on improvement of angina symptoms, TCM syndrome scores, blood stasis scores, reduction/cessation of short-acting anti-angina drugs, Seattle Angina Questionnaire (SAQ) scores, blood lipid levels, and matrix metalloproteinase-9 (MMP-9) concentrations between the two groups. [Results] No statistical differences existed in baseline data like age, gender, and disease duration between the two groups (P>0.05). The treatment group showed significantly better efficacy than the control group in improving angina symptoms, TCM syndrome scores, blood stasis scores, and reduction or discontinuation of short-acting anti-anginal drugs (P<0.05). The SAQ score increase was more significant in the treatment group (P<0.05). The control group significantly reduced low-density lipoprotein cholesterol (LDL-C) (P<0.05), while the treatment group markedly increased high-density lipoprotein cholesterol (HDL-C) (P<0.05). Post-treatment, the treatment group had a marked reduction in serum MMP-9 (P<0.05), with no significant change in the control group. [Conclusions] Qinjin Tablet can significantly alleviate clinical symptoms and improve quality of life in UA patients by modulating the HDL-C/MMP-9 signaling pathway. |
